The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival

Cancer

Volumn 110, Issue 8, 2007, Pages 1738-1744

  Kidd, Elizabeth A ^a   Siegel, Barry A ^a,b   Dehdashti, Farrokh ^a,b   Grigsby, Perry W ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervix; F 18 fluorodeoxyglucose positron emission tomography; Radiotherapy; Standardized uptake value

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DRUG TUMOR LEVEL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 35048861568     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22974     Document Type: Article

References (35)

1. Grigsby PW, Dehdashti E Siegel BA. FDG-PET evaluation of carcinoma of the cervix. Clin Pos Imaging. 1999;2:105-109.
2. Grigsby PW, Siegel BA, Dehdashti E Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745-3749.
3. 18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22:2167-2171.
4. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353-359.
5. Miller TR, Pinkus E, Dehdashti F, et al. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med. 2003;44:192-197.
6. Rose PG, Adler LP, Rodriguez M, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. 1999;17:41-45.
7. 18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol. 2004;6:55-62.
8. Allal AS, Slosman DO, Kebdani T, et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
9. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541.
10. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
11. Eschmann SM, Friedel G, Paulsen F, et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;33:263-269.
12. Kieninger AN, Welsh R, Bendick PJ, et al. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg. 2006;191:433-436.
13. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
14. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer out-comes. Arch Otolaryngol Head Neck Surg. 2004;130:1361-1367.
15. 18F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17:3201-3206.
16. Xue F, Lin LL, Dehdashti F, et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101:147-151.
17. Perez CA, Kavanagh BD. Uterine cervix. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia: Lippincott, Williams & Williams; 2003:1800-1915.
18. Wright JD, Dehdashti F, Herzog TJ, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer. 2005;104:2484-2491.
19. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Perez CA, Grigsby PW, Chao KSC, et al. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys. 1998;41:307-317.
22. Delgado G, Bundy BN, Fowler WC Jr, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;35:314-320.
23. Leveque J, Laurent JF, Burtin F, et al. Prognostic factors of the uterine cervix adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 1998;80:209-214.
24. Chen RJ, Chang DY, Yen ML, et al. Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol. 1998;69:157-164.
25. Pillot G, Siegel BA, Govindan R. Prognostic significance of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol. 2006;1:152-159.
26. Sachs S, Bilfinger TV, Komaroff E, et al. Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer. Clin Lung Cancer. 2005;6:310-313.
27. Hardt N, van Nagell JR, Hanson M, et al. Radiation-induced tumor regression as a prognostic factor in patients with invasive cervical cancer. Cancer. 1982;49:35-39.
28. Hong JH, Chen MS, Lin FJ, et al. Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 1992;22:913-917.
29. Lin LL, Yang Z, Mutic S, et al. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys. 2006;65:177-181.
30. Brown RS, Goodman TM, Zasadny KR, et al. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol. 2002;29:443-453.
31. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9-16.
32. Mendez LE, Manci N, Cantuaria G, et al. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol. 2002;86:138-143.
33. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934.
34. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22-29.
35. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Eur J Nucl Med Mol Imaging. 2004;31:5-12.